Floatz logo

su011248

Liver Cancer

Federation Francophone de Cancerologie DigestivePhase 2/3Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

83 Active assets in the Liver Cancer cohort.

Asset / SponsorPhaseRating
Inno-206
Shanghai Zhongshan Hospital
Phase 4BB
Eloxatin
Sun Yat-sen University
Phase 3BB
Sorafenib
First Affiliated Hospital Xi'an Jiaotong University
Phase 3BB
Idarubicine
Second Affiliated Hospital of Guangzhou Medical University
Phase 3BB
Ethiodized Oil
Sun Yat-sen University
Phase 4BB

View all 50 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →